Study ID: NHL-TL011-102
Study Title
- A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
Teva Identifier
- NHL-TL011-102
ClinicalTrials.gov Identifier
- NCT01205737
Study Status
- Completed
Trial Condition(s)
- DLBCL
Interventions
- Biological: TL011 | Biological: Rituximab
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years to 80 Years
Trial Duration
- 09/01/2010 - 09/01/2013
Phase
- Phase 1
Study Type
Interventional
